How the choice of assay and system influences results

Since its introduction in 2002, free light chains (FLC) testing has become crucial for diagnosing and managing monoclonal gammopathies. Recommendations from the International Myeloma Working Group (IMWG) and other societies rely heavily on serum free light chains (sFLC), particularly the involved/uninvolved FLC ratio, to indicate different stages of these disorders. Multiple assays and detection methodologies exist, with nephelometry known for its sensitivity advantage over turbidimetry. Siemens Healthineers highlights how the choice of assay and system significantly influences results, as shown by studies comparing polyclonal FREELITE^® assays and monoclonal N Latex FLC assays, revealing variations in sensitivity and performance.